Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1

Terminated

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Acapatamab
Drug: AMG 404
Drug: Enzalutamide
Drug: Abiraterone

First Posted Date: 2020-11-17

Last Posted Date: 2024-08-29

Lead Sponsor: Amgen

Target Recruit Count: 65

Registration Number: NCT04631601

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California at Irvine Medical Center, Orange, California, United States
🇺🇸
University of California San Francisco Mission Bay Campus, San Francisco, California, United States

and more 11 locations

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: ABP 654
Drug: Ustekinumab

First Posted Date: 2020-10-29

Last Posted Date: 2024-12-12

Lead Sponsor: Amgen

Target Recruit Count: 563

Registration Number: NCT04607980

Locations: 🇨🇦
Toronto Research Centre - Dermatology, Toronto, Ontario, Canada
🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇨🇦
DermEdge Research Inc., Mississauga, Ontario, Canada

and more 81 locations

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: Standard of care
Drug: Apremilast placebo
Drug: Lanadelumab placebo
Drug: Zilucoplan placebo
Drug: Lanadelumab
Drug: Apremilast
Drug: Zilucoplan

First Posted Date: 2020-10-19

Last Posted Date: 2022-06-29

Lead Sponsor: Amgen

Target Recruit Count: 515

Registration Number: NCT04590586

Locations: 🇺🇸
The University of Iowa, Iowa City, Iowa, United States
🇺🇸
Sharp Chula Vista Medical Center, Chula Vista, California, United States
🇷🇺
SPb SBIH "Alexandrovskaya City Hospital", Saint Petersburg, Russian Federation

and more 56 locations

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

Phase 4

Completed

Conditions: Chronic (Inactive) Thyroid Eye Disease
Thyroid Eye Disease

Interventions: Biological: TEPEZZA
Drug: Placebo

First Posted Date: 2020-10-12

Last Posted Date: 2024-07-01

Lead Sponsor: Amgen

Target Recruit Count: 62

Registration Number: NCT04583735

Locations: 🇺🇸
MACRO Trials, Los Angeles, California, United States
🇺🇸
Las Vegas Endocrinology, Las Vegas, Nevada, United States
🇺🇸
Bascom Palmer Eye Institute / Univ of Miami, Miami, Florida, United States

and more 9 locations

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

Phase 1

Terminated

Conditions: Obesity

Interventions: Drug: AMG 171
Drug: Placebo

First Posted Date: 2019-12-13

Last Posted Date: 2023-09-15

Lead Sponsor: Amgen

Target Recruit Count: 60

Registration Number: NCT04199351

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
Orange County Research Center, Tustin, California, United States

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: VIB4920
Drug: Placebo

First Posted Date: 2019-11-15

Last Posted Date: 2024-12-17

Lead Sponsor: Amgen

Target Recruit Count: 78

Registration Number: NCT04163991

Locations: 🇵🇱
Research Site, Warszawa, Poland

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-11050

First Posted Date: 2019-10-25

Last Posted Date: 2020-06-22

Lead Sponsor: Amgen

Target Recruit Count: 44

Registration Number: NCT04139226

Locations: 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

Phase 2

Completed

Conditions: Sjögren's Syndrome

Interventions: Drug: VIB4920
Drug: Placebo

First Posted Date: 2019-10-16

Last Posted Date: 2024-12-10

Lead Sponsor: Amgen

Target Recruit Count: 183

Registration Number: NCT04129164

Locations: 🇬🇧
Research Site, Truro, United Kingdom
🇺🇸
Research site, Dallas, Texas, United States

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Phase 1

Terminated

Conditions: MUC17-positive Solid Tumors

Interventions: Drug: AMG 199

First Posted Date: 2019-10-07

Last Posted Date: 2024-11-22

Lead Sponsor: Amgen

Target Recruit Count: 58

Registration Number: NCT04117958

Locations: 🇩🇪
Klinikum rechts der Isar, Muenchen, Germany
🇦🇹
Landeskrankenhaus Salzburg, Salzburg, Austria
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 18 locations

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: Rozibafusp Alfa
Drug: Placebo for Rozibafusp Alfa

First Posted Date: 2019-08-15

Last Posted Date: 2024-03-04

Lead Sponsor: Amgen

Target Recruit Count: 244

Registration Number: NCT04058028

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
The Emory Clinic, Atlanta, Georgia, United States
🇺🇸
Rheumatic Disease Clinical Research Center LLC, Houston, Texas, United States

and more 139 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy